DUPA is widely used in the development of prostate cancer imaging agents and targeted therapies. It serves as a high-affinity ligand for prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells. Due to this specificity, DUPA is conjugated with radiotracers for use in PET imaging, enabling precise detection and staging of prostate cancer. It is also explored in drug delivery systems, where it helps direct cytotoxic agents selectively to PSMA-positive tumor cells, minimizing damage to healthy tissues. Its role in theranostics—combining therapy and diagnostics—makes it valuable in personalized medicine for prostate cancer management.